Peter Ellmark
11 – 20 of 49
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
(
- Contribution to journal › Article
- 2020
-
Mark
Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer.
2020) The Society for Immunotherapy of Cancer's (SITC) 35th annual meeting In Journal for ImmunoTherapy of Cancer 8(Suppl. 3).(
- Contribution to journal › Published meeting abstract
- 2018
-
Mark
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
(
- Contribution to journal › Article
- 2017
-
Mark
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
(
- Contribution to journal › Article
-
Mark
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Selective FcγR engagement by human agonistic anti-CD40 antibodies
(
- Contribution to journal › Debate/Note/Editorial
- 2015
-
Mark
Kick-starting the cancer-immunity cycle by targeting CD40
(
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.
(
- Contribution to journal › Article
-
Mark
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
(
- Contribution to journal › Article
- 2009
-
Mark
Attovial-based antibody nanoarrays.
(
- Contribution to journal › Article